Fujirebio Inc., a leading diagnostic company based in Japan, has received approval from China’s National Medical Products Administration (NMPA) for its innovative hepatitis B virus surface antigen (HBsAg) detection kit, which utilizes the chemiluminescence method. This detection kit, comprising antibody binding particles, enzyme-labeled antibodies, and a sample processing solution, is designed for the qualitative and quantitative detection of HBsAg in human serum or plasma in vitro.
This product stands out in the market due to its superior sensitivity, enabling the detection of the hepatitis B virus surface antigen at concentrations as low as those present during the early stages of infection. This capability is crucial for facilitating early diagnosis and initiating prompt treatment, which can significantly impact patient outcomes in the management of hepatitis B. – Flcube.com
